Literature DB >> 3951094

Savings from outpatient antibiotic therapy for osteomyelitis. Economic analysis of a therapeutic strategy.

J M Eisenberg, D S Kitz.   

Abstract

Clinical, economic, and epidemiologic data were used to compare the costs of conventional inpatient care of osteomyelitis with the costs of early-discharge treatment using a once-daily parenteral antibiotic at home. Estimated expenses included inpatient medical care, outpatient visits, supplies, child care, home care, transportation, and lost productivity. Early-discharge treatment was associated with lower medical direct, non-medical direct, and indirect expenses than conventional inpatient treatment. Estimated savings per patient ranged from $510 to $22,232 (demonstrating the wide differences in estimated savings when different sources of data on hospital costs are used). These savings are due to large decreases in inpatient costs, which are partially offset by increased outpatient costs. However, because outpatient costs are more often borne by patients than are inpatient costs, early-discharge treatment could be more expensive from the patient's perspective, despite its savings for the hospital and for society as a whole.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3951094

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

Review 1.  Economics of home intravenous services.

Authors:  N D Thickson
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

2.  Home intravenous anti-infective therapy (HIVAT): do the benefits outweigh the risks?

Authors:  D N Williams
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

Review 3.  Rational prescribing of antibacterials in hospitalised children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

4.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

5.  Intramuscular ceftriaxone in home parenteral therapy.

Authors:  T A Russo; S Cook; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma.

Authors:  P C Coyte; M J Dobrow; L Broadfield
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Management of serious staphylococcal infections in the outpatient setting.

Authors:  W Graninger; E Presterl; C Wenisch; E Schwameis; S Breyer; T Vukovich
Journal:  Drugs       Date:  1997       Impact factor: 9.546

8.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

9.  Treatment of chronic traumatic bone wounds. Microvascular free tissue transfer: a 13-year experience in 96 patients.

Authors:  J W May; J B Jupiter; G G Gallico; D M Rothkopf; P Zingarelli
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

10.  Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis.

Authors:  W Graninger; C Wenisch; E Wiesinger; M Menschik; J Karimi; E Presterl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.